Trastuzumab Deruxtecan 100MG Injection – Benefits, Uses, Dosage & Side Effects

Trastuzumab Deruxtecan 100MG Injection is a prescription HER2-targeted antibody-drug conjugate used for selected patients with HER2-related cancers. It combines a HER2-targeting antibody with a chemotherapy payload and is administered by intravenous infusion under specialist medical supervision.

Uses of Trastuzumab Deruxtecan

Trastuzumab deruxtecan may be used for selected patients with:

HER2-positive breast cancer

HER2-low or HER2-ultralow breast cancer in applicable indications

HER2-mutant non-small cell lung cancer

HER2-positive gastric or gastroesophageal junction cancer

Certain other HER2-positive solid tumors

Treatment eligibility depends on cancer type, HER2 testing, previous treatment, and local regulatory approvals.

Benefits

Targets HER2-expressing cancer cells.

Delivers a cytotoxic drug payload to targeted cancer cells.

Provides an established treatment option for several HER2-related cancers.

May be used in advanced or metastatic cancer according to approved indications.

Dosage & Administration

The 100MG refers to the vial strength, not necessarily the patient's individual dose.

Common dosing includes:

5.4 mg/kg IV every 3 weeks for several approved indications.

6.4 mg/kg IV every 3 weeks for applicable gastric/GEJ cancer indications.

The exact dose must be determined by an oncologist. It should be administered only by trained healthcare professionals.

Side Effects

Common side effects may include:

Nausea and vomiting

Fatigue

Decreased appetite

Diarrhea or constipation

Hair loss

Low blood-cell counts

Anemia

Increased liver enzymes

Muscle or joint pain

Serious Risks

Important risks include interstitial lung disease/pneumonitis, neutropenia, and heart problems. New cough, breathing difficulty, fever, chest symptoms, or severe weakness should be reported immediately.

Trastuzumab Deruxtecan in USA, UK, UAE & South Africa

Trastuzumab deruxtecan is used for approved oncology indications in the USA, UK, UAE and South Africa, subject to country-specific regulatory requirements. Hospitals, oncology centers, pharmacies, and authorized distributors should verify current local registration and import requirements before procurement.

FAQs

What is Trastuzumab Deruxtecan 100MG Injection?

It is a HER2-targeted antibody-drug conjugate used for selected HER2-related cancers.

Is 100MG the dose for every patient?

No. 100MG is the vial strength. The prescribed dose is generally calculated according to body weight and indication.

How often is it given?

Many approved indications use treatment every three weeks, but the dosage varies by cancer type.

Can it be self-administered?

No. It must be prepared and administered by qualified healthcare professionals.

What is the major warning?

Interstitial lung disease/pneumonitis is a serious potential risk. Respiratory symptoms require immediate medical evaluation.

Does treatment require HER2 testing?

Yes, appropriate HER2 testing is required for indications based on HER2 status or HER2 mutation.

Is it the same as Trastuzumab?

No. Trastuzumab deruxtecan is an antibody-drug conjugate containing a cytotoxic payload.

Conclusion

Trastuzumab Deruxtecan 100MG Injection is an important targeted oncology medicine for selected HER2-related cancers. Its use and dosage should always be determined by a qualified oncologist based on the patient's diagnosis and current treatment guidelines.

Medical Disclaimer: This information is for educational purposes only and does not replace professional medical advice or a prescription.